• 主页
  • 查找结果
  • Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry.

Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry.

British journal of haematology (2014-07-06)
Caterina Borgna-Pignatti, Maria Chiara Garani, Gian Luca Forni, Maria Domenica Cappellini, Elena Cassinerio, Carmelo Fidone, Vincenzo Spadola, Aurelio Maggio, Gaetano Restivo Pantalone, Antonio Piga, Filomena Longo, Maria Rita Gamberini, Paolo Ricchi, Silvia Costantini, Domenico D'Ascola, Paolo Cianciulli, Maria Eliana Lai, Maria Paola Carta, Angela Ciancio, Paola Cavalli, Maria Caterina Putti, Susanna Barella, Giovanni Amendola, Saveria Campisi, Marcello Capra, Vincenzo Caruso, Grazia Colletta, Stefano Volpato
摘要

The risk of developing hepatocellular carcinoma (HCC) in patients with thalassaemia is increased by transfusion-transmitted infections and haemosiderosis. All Italian Thalassaemia Centres use an ad hoc form to report all diagnoses of HCC to the Italian Registry. Since our last report, in 2002, up to December 2012, 62 new cases were identified, 52% of whom were affected by thalassaemia major (TM) and 45% by thalassaemia intermedia (TI). Two had sickle-thalassaemia (ST). The incidence of the tumour is increasing, possibly because of the longer survival of patients and consequent longer exposure to the noxious effects of the hepatotropic viruses and iron. Three patients were hepatitis B surface antigen-positive, 36 patients showed evidence of past infection with hepatitis B virus (HBV). Fifty-four patients had antibodies against hepatitis C virus (HCV), 43 of whom were HCV RNA positive. Only 4 had no evidence of exposure either to HCV or HBV. The mean liver iron concentration was 8 mg/g dry weight. Therapy included chemoembolization, thermoablation with radiofrequency and surgical excision. Three patients underwent liver transplant, 21 received palliative therapy. As of December 2012, 41 patients had died. The average survival time from HCC detection to death was 11·5 months (1·4-107·2 months). Ultrasonography is recommended every 6 months to enable early diagnosis of HCC, which is crucial to decrease mortality.

材料
货号
品牌
产品描述

Sigma-Aldrich
铁, ≥99%, reduced, powder (fine)
Sigma-Aldrich
羰基铁, ≥97% Fe basis
Sigma-Aldrich
铁蛋白 来源于马脾脏, Type I, saline solution
Sigma-Aldrich
铁, powder, −325 mesh, 97%
Sigma-Aldrich
铁, powder, <10 μm, ≥99.9% trace metals basis
Sigma-Aldrich
铁, chips, 99.98% trace metals basis
Sigma-Aldrich
铁, nanopowder, 35-45 nm particle size, 99.5% trace metals basis
Sigma-Aldrich
铁, puriss. p.a., carbonyl-Iron powder, low in magnesium and manganese compounds, ≥99.5% (RT)
Sigma-Aldrich
铁, granular, 10-40 mesh, >99.99% trace metals basis
Sigma-Aldrich
铁, foil, thickness 0.1 mm, ≥99.9% trace metals basis
Sigma-Aldrich
铁, flakes, ≥99.99% trace metals basis
Sigma-Aldrich
铁, foil, thickness 0.25 mm, ≥99.99% trace metals basis
Sigma-Aldrich
铁, wire, diam. 1.0 mm, ≥99.9% trace metals basis
Sigma-Aldrich
铁, carbon coated magnetic, nanopowder, 25 nm avg. part. size, 99.5% trace metals basis
Sigma-Aldrich
铁蛋白 来源于人类脾脏, Type V, 10 μg/mL in 0.15 M NaCl, 10 mM Tris, pH 8.0, containing 0.1% sodium azide
铁, IRMM®, certified reference material, 0.5 mm wire
铁, foil, 300x300mm, thickness 0.1mm, hard, 99.5%
Sigma-Aldrich
铁, rod, diam. 6.3 mm, 99.98% trace metals basis
铁, foil, 25x25mm, thickness 1.0mm, as rolled, 99.5%
铁, foil, 100x100mm, thickness 1.0mm, as rolled, 99.99+%
铁, foil, 25x25mm, thickness 2mm, as rolled, 99.99+%
铁, foil, 100x100mm, thickness 0.5mm, hard, 99.5%
铁, foil, 150x150mm, thickness 3.0mm, as rolled, 99.5%
铁, rod, 100mm, diameter 2.0mm, as drawn, 99.95%
铁, rod, 200mm, diameter 2.0mm, as drawn, 99.99+%
铁, rod, 500mm, diameter 9.5mm, as drawn, soft ingot 99.8+%
铁, foil, 10mm disks, thickness 0.01mm, 99.85%
铁, foil, 10mm disks, thickness 0.01mm, 99.99+%
铁, foil, 10mm disks, thickness 0.020mm, 99.85%
铁, foil, 10mm disks, thickness 0.025mm, as rolled, 99.99+%